These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558 [TBL] [Abstract][Full Text] [Related]
8. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024 [TBL] [Abstract][Full Text] [Related]
9. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance]. Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769 [TBL] [Abstract][Full Text] [Related]
10. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Hoff PM Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060 [TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents. Hoff PM; Pazdur R Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of S-1]. Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969 [TBL] [Abstract][Full Text] [Related]
15. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. Ogura K Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
17. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105 [TBL] [Abstract][Full Text] [Related]